Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Whoop is no longer just for elite athletes. The wearable company is expanding into clinical care with FDA-cleared ECG, EHR integration, on-demand physician access, and blood diagnostics — positioning its 24/7 biometric monitoring as a continuous alternative to the annual physical. With 3.5 million members and a $10 billion valuation, Whoop is betting that always-on health data can bridge the gap between consumers and the healthcare system.
Whoop started as a performance wearable for Olympians and pro athletes, but the company is now making a serious push into clinical healthcare. At HLTH 2026 in Las Vegas, CEO Will Ahmed laid out a vision where continuous biometric monitoring replaces the "frozen in time" annual physical — combining wearable data with blood tests, medical records, and AI-driven insights to catch health problems before they escalate.
The platform now includes an FDA-cleared ECG for atrial fibrillation detection, EHR syncing via a partnership with HealthEx, on-demand clinician video consultations, and expanded lab testing that incorporates Grail's multi-cancer early detection test. A new partnership with Novo Nordisk integrates Whoop data into the pharma giant's NovoCare GLP-1 support program. Whoop is also participating in CMS's ACCESS model, which ties government reimbursement to measurable health outcomes — a shift Ahmed sees as a major validation of the wearable-as-healthcare model.
By the Numbers:
Why it matters: As wearables grow more clinically capable, Whoop's model — continuous monitoring layered with diagnostics, AI, and physician access — could reshape how patients and providers interact between office visits, especially for older adults and those managing chronic conditions.